Company announced to launch BREVAGen™- world’s first validated test for non-familial breast cancer in the first quarter 2011.
cancer prognostic test in this quarter with a U.S> market target of 1 million patients per annum.
The Company has identified three target markets for its test: BRCA negative patients, breast biopsy patients and women over 35 having a family history of cancer.
The test combines population risk factors with genetic risk factors to give integrated individual breast cancer risk assessment. BREVAGen test also informs personalized clinical decision support for non-familial risk of breast cancer and is the first fully peer reviewed validated test of its kind.
The Company had through references estimated that the U.S. market for existing breast cancer molecular diagnostics was about $690 million in 2006 and has grown at almost 18% CAGR since.
The Company identifies BREVAGen to have an attractive CoGS, ROI and payback with a large, characterized and global market.
Genetic Technologies Limited is engaged in a diagnostic product business. The Company translates genetic tests into products and services. The Company’s cancer diagnostics business focused on building a sustainable stable of products and services.